These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 21561355

  • 1. Advances in pancreatic neuroendocrine tumor treatment.
    van der Veldt AA, Kleijn SA.
    N Engl J Med; 2011 May 12; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
    [No Abstract] [Full Text] [Related]

  • 2. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT, Delle Fave G.
    N Engl J Med; 2011 Feb 10; 364(6):564-5. PubMed ID: 21306243
    [No Abstract] [Full Text] [Related]

  • 3. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G, Katsios C, Roukos DH.
    Expert Rev Gastroenterol Hepatol; 2011 Oct 10; 5(5):563-6. PubMed ID: 21910571
    [No Abstract] [Full Text] [Related]

  • 4. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
    Barna ME, Uomo I, Pastorello M.
    JOP; 2013 Jan 10; 14(1):102-4. PubMed ID: 23306347
    [No Abstract] [Full Text] [Related]

  • 5. Advances in the treatment of pancreatic neuroendocrine tumours.
    Gao F, Visvardis EE, Sita-Lumsden A, Waxman J.
    QJM; 2012 Sep 10; 105(9):819-22. PubMed ID: 22383691
    [Abstract] [Full Text] [Related]

  • 6. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
    Raymond E, Ruszniewski P.
    Target Oncol; 2012 Jun 10; 7(2):91-2. PubMed ID: 22669625
    [No Abstract] [Full Text] [Related]

  • 7. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
    Crippa S, Partelli S, Boninsegna L, Falconi M.
    Ann Oncol; 2012 Jul 10; 23(7):1928. PubMed ID: 22753260
    [No Abstract] [Full Text] [Related]

  • 8. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
    Liakakos T, Roukos DH.
    Future Oncol; 2011 Sep 10; 7(9):1025-9. PubMed ID: 21919689
    [No Abstract] [Full Text] [Related]

  • 9. Recent studies show promise for treating rare pancreatic tumors.
    Peres J.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):624-7. PubMed ID: 21474831
    [No Abstract] [Full Text] [Related]

  • 10. Advances in pancreatic neuroendocrine tumor treatment.
    Castellano D, Grande E, Barriuso J.
    N Engl J Med; 2011 May 12; 364(19):1872-3; author reply 1873-4. PubMed ID: 21561356
    [No Abstract] [Full Text] [Related]

  • 11. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R, Libutti SK, Saif MW.
    JOP; 2013 Mar 10; 14(2):152-4. PubMed ID: 23474560
    [Abstract] [Full Text] [Related]

  • 12. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN, Syrigos KN, Saif MW.
    JOP; 2014 Jul 28; 15(4):351-3. PubMed ID: 25076341
    [Abstract] [Full Text] [Related]

  • 13. [Erlotinib, sunitinib, and everolimus].
    Takahashi M.
    Nihon Rinsho; 2015 Mar 28; 73 Suppl 3():409-13. PubMed ID: 25857058
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J, Tabernero J.
    Cancer Discov; 2011 Aug 28; 1(3):213-21. PubMed ID: 22586573
    [Abstract] [Full Text] [Related]

  • 16. [Recent progress in the molecular-targeting treatment of neuroendocrine tumors].
    Unno M.
    Nihon Shokakibyo Gakkai Zasshi; 2010 Mar 28; 107(3):392-5. PubMed ID: 20203442
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L, Schwarz RE.
    Curr Mol Med; 2013 Mar 28; 13(3):333-9. PubMed ID: 23331005
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Steve Jobs's cancer. Pancreatic neuroendocrine tumors are becoming more common (the bad news) and also more treatable (the good news).
    Harv Health Lett; 2012 Jan 28; 37(3):1-3. PubMed ID: 22400158
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.